Details for Patent: 8,198,242
✉ Email this page to a colleague
Which drugs does patent 8,198,242 protect, and when does it expire?
Patent 8,198,242 protects VOXZOGO and is included in one NDA.
This patent has forty-five patent family members in twenty-four countries.
Summary for Patent: 8,198,242
| Title: | Variants of C-type natriuretic peptide |
| Abstract: | The present disclosure provides variants of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising CNP variants, and methods of making CNP variants. The CNP variants are useful as therapeutic agents for the treatment of diseases responsive to CNP, including but not limited to bone-related disorders, such as skeletal dysplasias (e.g., achondroplasia), and vascular smooth muscle disorders (e.g., restenosis and arteriosclerosis). |
| Inventor(s): | Wendt; Daniel J. (Walnut Creek, CA), Long; Shinong (Milpitas, CA), Castillo; Sianna (San Francisco, CA), Price; Christopher P. (Kentfield, CA), Aoyagi-Scharber; Mika (Mill Valley, CA), Vellard; Michel C. (San Rafael, CA), Okhamafe; Augustus O. (Concord, CA) |
| Assignee: | Biomarin Pharmaceutical Inc. (Novato, CA) |
| Application Number: | 12/784,117 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; |
Drugs Protected by US Patent 8,198,242
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biomarin Pharm | VOXZOGO | vosoritide | POWDER;SUBCUTANEOUS | 214938-001 | Nov 19, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | USE TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WHO ARE 5 YEARS OF AGE AND OLDER WITH OPEN EPIPHYSES | ⤷ Try a Trial | ||
| Biomarin Pharm | VOXZOGO | vosoritide | POWDER;SUBCUTANEOUS | 214938-002 | Nov 19, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | USE TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WHO ARE 5 YEARS OF AGE AND OLDER WITH OPEN EPIPHYSES | ⤷ Try a Trial | ||
| Biomarin Pharm | VOXZOGO | vosoritide | POWDER;SUBCUTANEOUS | 214938-003 | Nov 19, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | USE TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WHO ARE 5 YEARS OF AGE AND OLDER WITH OPEN EPIPHYSES | ⤷ Try a Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,198,242
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 078044 | ⤷ Try a Trial | |||
| Argentina | 120933 | ⤷ Try a Trial | |||
| Australia | 2010249802 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
